J1I-MC-GZQD: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain (TRIUMPH-7)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517431-43-00

Acronym

J1I-MC-GZQD

Enrollment

Registered

2025-04-06

Start date

Unknown

Completion date

2025-10-06

Last updated

2025-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight, Chronic Low Back Pain (CLBP), Obesity

Brief summary

Change from Baseline in Weekly Average Pain Intensity-Numeric Rating Scale (API-NRS) Score [Time Frame: Baseline, up to 72 weeks], Percent Change from Baseline in Body Weight [Time Frame: Baseline, up to 72 weeks]

Interventions

DRUGPlacebo to match LY

DRUGRetatrutide

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from Baseline in Weekly Average Pain Intensity-Numeric Rating Scale (API-NRS) Score [Time Frame: Baseline, up to 72 weeks], Percent Change from Baseline in Body Weight [Time Frame: Baseline, up to 72 weeks]	—

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026